This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Idiopathic normal-pressure hydrocephalus (iNPH) is a reversible syndrome of gait impairment, dementia, and incontinence that affects persons over 65 years of age.1 Currently, the only effective treatment is surgical implantation of a shunt2; however, the need for pharmacologic adjunctive treatments was noted at the 2005 NIH workshop on hydrocephalus.3
Footnotes
Study funding: No targeted funding reported.
Disclosure: M. Williams has been the Associate Editor for Ethics for Continuum since 2005. He holds the following patents: July 1, 2003: Shunt: United States Patent 6,585,677. August 17, 2004: Shunt: Canadian Patent 2,356,032. August 23, 2005: Shunt: United States Patent 6,932,787 B2. Continuation of US Patent 6,585,677. June 8, 2006: Self-sealing catheter for deformable tissue: International Patent WO 2006/060181 A1. M. Williams owns a 5% interest in Mensana Therapeutics, a start-up with intellectual property only that is related to CSF shunting for the treatment of Alzheimer dementia. M. Williams is the President in the International Society for Hydrocephalus and CSF Disorders for 2012–2014. Go to Neurology.org for full disclosures.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH
Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response
Vascular risk factors in INPH
Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus